Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 with Donepezil in Moderate to Severe Alzheimer's Disease
NCT03184467Phase 2Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tertomotide in Alzheimer's disease (AD), sponsored by GemVax & KAEL Co., Ltd.. Started Sep 2017; status: completed.
02
Drugs
tertomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03184467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184467.